Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 93Carcinoma, Non-Small-Cell Lung 46Neoplasms 33Carcinoma, Renal Cell 24Neoplasm Metastasis 16Colorectal Neoplasms 13Carcinoma, Hepatocellular 12Small Cell Lung Carcinoma 9Prostatic Neoplasms 9Lung Neoplasms 9Diabetes Mellitus, Insulin-Dependent, 12 9Advanced Cancer 9Squamous Cell Carcinoma of Head and Neck 8Uveal Melanoma 7Stomach Neoplasms 7Skin Neoplasms 7Mesothelioma 7Kidney Neoplasms 7Carcinoma, Transitional Cell 7Recurrence 6Pancreatic Neoplasms 6Liver Neoplasms 6Triple Negative Breast Neoplasms 5Sarcoma 5Ovarian Neoplasms 5Head and Neck Neoplasms 5Endometrial Neoplasms 5Breast Neoplasms 5Uterine Cervical Neoplasms 4Solid Tumor 4

Interventions

Gemcitabine 4Cisplatin 4Carboplatin 3pembrolizumab 2erdafitinib 2vinflunine 1tremelimumab 1enfortumab vedotin 1durvalumab 1avelumab 1atezolizumab 1Tiragolumab 1Sunitinib 1Nivolumab 1Midazolam 1Metformin 1Ipilimumab 1Docetaxel 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Urothelial Cancer × Ipilimumab × Clear all
NCT03036098 2026-03-06

CheckMate901

Bristol-Myers Squibb

Phase 3 Active not recruiting
1,314 enrolled 23 charts 1 FDA
Genitourinary

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡